Physician profile
James Yoss
NPI 1932107109
$4,899.28
in general payments reported to CMS, 2019-2025
30 companies · $753 in 2025
The $753 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $631 · 2022: $168 · 2023: $851 · 2024: $1,275 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862 · Education: $17.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,862.07 |
| Education | $17.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,391.53 | 2019-2025 | Cabenuva, Rukobia, Dovato |
| Merck Sharp & Dohme LLC | $402.13 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Gilead Sciences, INC. | $375.09 | 2019-2025 | |
| Pfizer INC. | $355.78 | 2019-2025 | |
| Novo Nordisk INC | $332.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.42 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $235.50 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $215.89 | 2020-2025 | Viberzi, Linzess, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $165.44 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Theratechnologies INC. | $163.92 | 2022-2025 | Trogarzo, Egrifta |
| Lilly USA, LLC | $163.42 | 2019-2024 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $157.74 | 2019-2023 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $95.53 | 2024-2025 | |
| Janssen Biotech, INC. | $92.09 | 2019 | |
| Astellas Pharma US INC | $72.74 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $70.52 | 2023-2025 | Evenity, Prolia, Prolia |
| Circassia INC. | $50.59 | 2019-2020 | |
| Sanofi Pasteur INC. | $47.32 | 2019-2020 | |
| Allergan, INC. | $42.52 | 2019-2020 | |
| Eisai INC. | $32.54 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $24.00 | 2019 | |
| Bausch Health US, LLC | $23.20 | 2023 | Aplenzin |
| Xeris Pharmaceuticals, INC. | $23.10 | 2024 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $22.59 | 2019 | |
| Edwards Lifesciences Corporation | $21.91 | 2020 | |
| Napo Pharmaceuticals INC | $21.52 | 2023 | Mytesi |
| Exact Sciences Corporation | $16.81 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $15.99 | 2020 | |
| Radius Health, INC. | $15.92 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Yoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.